Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo
- PMID: 8050198
- DOI: 10.1006/clin.1994.1137
Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo
Abstract
Murine systems have demonstrated improved anti-tumor efficacy when tumor-infiltrating lymphocytes (TIL) are combined with interleukin-2 (IL-2). One goal of human adoptive immunotherapy is to identify and expand TIL with specific activity against autologous tumor. In this study we attempted to isolate and characterize such cells by phenotype and cytokine expression pattern. Fourteen unselected (bulk) TIL and 5 CD8+ selected cultures were established from primary renal cell carcinoma. All cultures were grown in the presence of IL-2; triplicate cultures of each TIL culture were grown in IL-2 alone or were intermittently cocultured with irradiated allogeneic or autologous tumor. The in vitro cytotoxicity, phenotype, and cytokine expression pattern as defined by the secretion of tumor necrosis factor-alpha (TNF-alpha), interferon-gamma, granulocyte-macrophage colony-stimulating factor, IL-4, IL-6, and IL-12 were evaluated for each culture. While there was significant heterogeneity among the cultures under differing culture conditions as characterized by cytotoxicity, phenotype, and cytokine secretion pattern, we identified 8 TIL cultures which demonstrated specific enhanced lysis of only autologous tumor upon exposure to irradiated autologous tumor in vitro. These cultures demonstrate a decreased proportion of cells expressing the phenotype CD11b+. More importantly, these cultures were defined by the cytokine secretion phenotype TNF(+)/IL-6(-) upon exposure to irradiated autologous tumor. When utilized in vivo in adoptive immunotherapy of metastatic renal cell carcinoma together with IL-2, complete resolution of all metastatic tumor has only been achieved in patients who received TIL with the cytokine profile TNF(+)/IL-6(-). These findings suggest that tumor-specific renal TIL with enhanced tumor-specific cytotoxicity can be generated in vitro and can be characterized by a specific pattern of cytokine secretion. In addition, patients who receive TIL characterized by the cytokine profile TNF(+)/IL-6(-) may have an improved outcome when receiving immunotherapy.
Similar articles
-
Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma.J Immunother (1991). 1991 Oct;10(5):347-54. doi: 10.1097/00002371-199110000-00006. J Immunother (1991). 1991. PMID: 1790142
-
Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.J Clin Oncol. 1995 Aug;13(8):1939-49. doi: 10.1200/JCO.1995.13.8.1939. J Clin Oncol. 1995. PMID: 7636534 Clinical Trial.
-
Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):149-61. doi: 10.1097/00002371-199603000-00008. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8732698 Clinical Trial.
-
Immunotherapy of renal cell carcinoma.CA Cancer J Clin. 1993 May-Jun;43(3):177-87. doi: 10.3322/canjclin.43.3.177. CA Cancer J Clin. 1993. PMID: 8490757 Review.
-
Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.J Immunother Cancer. 2018 Oct 3;6(1):102. doi: 10.1186/s40425-018-0391-1. J Immunother Cancer. 2018. PMID: 30285902 Free PMC article. Review.
Cited by
-
The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma.Br J Cancer. 1995 Jul;72(1):101-7. doi: 10.1038/bjc.1995.284. Br J Cancer. 1995. PMID: 7599037 Free PMC article.
-
In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.J Clin Invest. 1996 Jan 15;97(2):515-21. doi: 10.1172/JCI118443. J Clin Invest. 1996. PMID: 8567975 Free PMC article.
-
Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13.Clin Exp Immunol. 1995 May;100(2):277-83. doi: 10.1111/j.1365-2249.1995.tb03665.x. Clin Exp Immunol. 1995. PMID: 7743667 Free PMC article.
-
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.J Cancer Res Clin Oncol. 1997;123(6):317-24. doi: 10.1007/BF01438307. J Cancer Res Clin Oncol. 1997. PMID: 9222297 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials